

# Julia A Elvin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2144157/julia-a-elvin-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

2,613  
citations

24  
h-index

51  
g-index

62  
ext. papers

3,503  
ext. citations

6.7  
avg, IF

4.28  
L-index

#	Paper	IF	Citations
60	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , <b>2021</b> ,	6.4	6
59	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. <i>Oncologist</i> , <b>2021</b> , 26, 375-382	5.7	0
58	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , <b>2021</b> , 12, 2487	17.4	24
57	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	1
56	Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1069-1071	4.5	1
55	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , <b>2021</b> , 26, e394-e402	5.7	9
54	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. <i>Modern Pathology</i> , <b>2021</b> , 34, 358-370	9.8	3
53	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. <i>Modern Pathology</i> , <b>2021</b> , 34, 1425-1433	9.8	3
52	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. <i>Modern Pathology</i> , <b>2020</b> , 33, 2614-2625	9.8	5
51	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. <i>Modern Pathology</i> , <b>2020</b> , 33, 2397-2406	9.8	9
50	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	7
49	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. <i>Modern Pathology</i> , <b>2020</b> , 33, 1466-1474	9.8	9
48	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , <b>2020</b> , 77, 548-556	10.2	19
47	Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 32-37	4.9	9
46	-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of $\beta$ -Wild-Type Tumor With Frequent Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	1
45	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. <i>European Urology Focus</i> , <b>2019</b> , 5, 748-755	5.1	11
44	Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 461-466	4.9	19

43	Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations. <i>Blood</i> , <b>2019</b> , 134, 2541-2541	2.2	2
42	Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA. <i>Blood</i> , <b>2019</b> , 134, 4659-4659	2.2	0
41	Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency. <i>Blood</i> , <b>2019</b> , 134, 1437-1437	2.2	0
40	Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. <i>Journal of Urology</i> , <b>2019</b> , 201, 541-548	2.5	36
39	Genomic Landscape of Adult and Pediatric -Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. <i>Oncologist</i> , <b>2019</b> , 24, 372-374	5.7	2
38	Tumor Mutational Burden Guides Therapy in a Treatment Refractory Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , <b>2018</b> , 23, 518-523	5.7	30
37	Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer. <i>Journal of Physical Education and Sports Management</i> , <b>2018</b> , 4,	2.8	2
36	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. <i>Oncologist</i> , <b>2018</b> , 23, 776-781	5.7	7
35	Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung Cancer. <i>Case Reports in Oncology</i> , <b>2018</b> , 11, 399-403	1	1
34	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , <b>2018</b> , 73, 71-78	10.2	54
33	in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	8
32	Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	22
31	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , <b>2018</b> , 8, 822-835	24.4	648
30	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 597-602	4.4	31
29	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. <i>Cancer Research</i> , <b>2017</b> , 77, 2464-2475	10.1	71
28	Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 20, 62-66	1.3	14
27	A recurrent endometrial stromal sarcoma harbors the novel fusion. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 20, 51-53	1.3	26
26	Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. <i>Oncologist</i> , <b>2017</b> , 22, 1444-1450	5.7	50

25	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. <i>Human Pathology</i> , <b>2017</b> , 70, 84-91	3.7	13
24	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , <b>2017</b> , 171, 1042-1056.e10	56.2	417
23	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. <i>Cancer</i> , <b>2017</b> , 123, 3628-3637	6.4	30
22	TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	6
21	reversion mutation acquired after treatment identified by liquid biopsy. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 21, 57-60	1.3	19
20	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 21, 78-80	1.3	13
19	Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. <i>Oncologist</i> , <b>2017</b> , 22, 834-842	5.7	26
18	Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 6061-6068	12.9	81
17	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , <b>2016</b> , 2, 204-209	5.1	30
16	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 2-9	4.9	26
15	Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. <i>Oncologist</i> , <b>2016</b> , 21, 33-9	5.7	55
14	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 405-13	4.4	13
13	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3281-5	12.9	22
12	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , <b>2016</b> , 70, 516-21	10.2	61
11	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. <i>Journal of Clinical Pathology</i> , <b>2016</b> , 69, 403-8	3.9	40
10	Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 1345-1350	7.3	18
9	Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. <i>Oncologist</i> , <b>2016</b> , 21, 684-91	5.7	61
8	The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 881-90	7.5	168

7	FGFR3-TACC3: A novel gene fusion in cervical cancer. <i>Gynecologic Oncology Reports</i> , <b>2015</b> , 13, 53-6	1.3	43
6	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 155-62	4.4	57
5	STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 66	22.4	56
4	Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. <i>Oncoscience</i> , <b>2015</b> , 2, 581-4	0.8	6
3	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 3561-4	4.4	6
2	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. <i>JAMA Oncology</i> , <b>2015</b> , 1, 40-49	13.4	137
1	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , <b>2015</b> , 20, 1132-9	5.7	69